AI made execution free. Knowing first is the whole game now.

The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.

Trusted by

OracleSnowflakeCloudflareLinkedInGoogleSalesforce

4.8/5 on G2· Since 2015

Everest Biolabs receives $2.1M SBIR grant from NIH to expand R&D operations.

Sep 26, 2026

WalthamBiotechnologyHealth CareLife Science

Description

Everest Biolabs, a Waltham, MA-based provider of automated extracellular vesicle isolation and analytics solutions, received a $2.1M Small Business Innovation Research (SBIR) Direct-to-Phase II grant from the National Institute of General Medical Sciences (NIGMS), part of the National Institutes of Health (NIH). The company plans to use the funds to expand operations and R&D efforts. Everest Biolabs provides automated, high-throughput tools for EV research and isolation, enabling researchers to cleanly isolate EVs from complex biofluids.

Company Information

Company

Everest Biolabs

Location

Waltham, Massachusetts, United States

About

Everest Biolabs is a life sciences company committed to providing essential tools for extracellular vesicle (EV) and exosome research. They focus on automating EV isolation and delivering standardized analytical tools to enhance researchers' workflows. Their innovative products aim to simplify and scale the research process, enabling scientists to focus on advancing clinical applications. With a mission to unlock the potential of EVs in clinical settings, Everest Biolabs upholds a strong commitment to innovation and scientific integrity.